Table 2 Innate immunity in the human FGT
Lower genital tract (LGT) (ectocervix and vagina) | Proliferative (E2 dominant) | Secretory (P4 dominant) | References |
|---|---|---|---|
Soluble factors (AMPs, HBD2, elafin) | ↓HBD2 and elafin | ↑SLPI | |
Epithelial cells (multilayered, squamous) | Thick vaginal epithelium | Thinner vaginal epithelium | |
Neutrophils | (=) | (=) | |
Macrophages | Vagina (=) | Vagina (=) | |
NK cells (CD45+, CD56+CD3− CD16+) | (=) | (=) |
Upper genital tract (UGT) (Endocervix and endometrium, fallopian tubes, and ovaries) | Proliferative (E2 dominant) | Secretory (P4 dominant) | References |
|---|---|---|---|
Soluble factors (AMPs, HBDs, elafin) | ↑HBD4 (endometrium) (note: HBD2 and elafin peak during menstruation) SLPI and elafin (fallopian tubes—constitutively expressed) | ↑SLPI, HBD1, HBD3 (endometrium) (maximal expression) | |
PRRs (TLR, NOD-1, 2) | TLR10 (fallopian tubes) TLRs 1–7 but not TLR4 (endocervix) | TLRs 2, 3 5, 6, 9, including TLR4)↑(endometrium), TLR10↑(fallopian tubes) | |
Epithelial cells (single layer, columnar) | Thick uterine epithelium. Constitutively express IFN-É› (Type 1 IFN) in luminal and glandular cells highest in the proliferative phase | Thin uterine epithelium | |
Neutrophils | (=) | Endometrial↑ | |
Macrophages |  | Endometrial↑ (before menstruation) | |
Dendritic cells | CD83+ (=) | CD1a+↑ | |
NK cells CD45+, CD56+CD3−CD16−, CD69+ CD94+ | uNK ↑CTL activity | Endometrial NK cells (with NKG2D receptor) ↑MICA uNK ↓CTL activity via IL-18 |